Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820
compared with non-treatment in patients with strabismus based on angles of strabismus in the
primary position.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA